231 related articles for article (PubMed ID: 30368521)
1. Cell cycle inhibitors protect motor neurons in an organoid model of Spinal Muscular Atrophy.
Hor JH; Soh ES; Tan LY; Lim VJW; Santosa MM; Winanto ; Ho BX; Fan Y; Soh BS; Ng SY
Cell Death Dis; 2018 Oct; 9(11):1100. PubMed ID: 30368521
[TBL] [Abstract][Full Text] [Related]
2. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
[TBL] [Abstract][Full Text] [Related]
3. Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells.
Lin X; Li JJ; Qian WJ; Zhang QJ; Wang ZF; Lu YQ; Dong EL; He J; Wang N; Ma LX; Chen WJ
Oncotarget; 2017 Jun; 8(26):42030-42042. PubMed ID: 28159932
[TBL] [Abstract][Full Text] [Related]
4. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific models of spinal muscular atrophy confirm a critical role of SMN in motor neurons from embryonic to adult stages.
Laird AS; Mackovski N; Rinkwitz S; Becker TS; Giacomotto J
Hum Mol Genet; 2016 May; 25(9):1728-38. PubMed ID: 26908606
[TBL] [Abstract][Full Text] [Related]
6. Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model.
Ando S; Funato M; Ohuchi K; Kameyama T; Inagaki S; Seki J; Kawase C; Tsuruma K; Shimazawa M; Kaneko H; Hara H
Eur J Pharmacol; 2017 Nov; 814():161-168. PubMed ID: 28826912
[TBL] [Abstract][Full Text] [Related]
7. Proteomic assessment of a cell model of spinal muscular atrophy.
Wu CY; Whye D; Glazewski L; Choe L; Kerr D; Lee KH; Mason RW; Wang W
BMC Neurosci; 2011 Mar; 12():25. PubMed ID: 21385431
[TBL] [Abstract][Full Text] [Related]
8. Calpain system is altered in survival motor neuron-reduced cells from in vitro and in vivo spinal muscular atrophy models.
de la Fuente S; Sansa A; Hidalgo I; Vivancos N; Romero-Guevara R; Garcera A; Soler RM
Cell Death Dis; 2020 Jun; 11(6):487. PubMed ID: 32587237
[TBL] [Abstract][Full Text] [Related]
9. Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability.
Liu H; Lu J; Chen H; Du Z; Li XJ; Zhang SC
Sci Rep; 2015 Jul; 5():12189. PubMed ID: 26190808
[TBL] [Abstract][Full Text] [Related]
10. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy.
Xu CC; Denton KR; Wang ZB; Zhang X; Li XJ
Dis Model Mech; 2016 Jan; 9(1):39-49. PubMed ID: 26586529
[TBL] [Abstract][Full Text] [Related]
11. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Burghes AH; Beattie CE
Nat Rev Neurosci; 2009 Aug; 10(8):597-609. PubMed ID: 19584893
[TBL] [Abstract][Full Text] [Related]
12. Astrocytes influence the severity of spinal muscular atrophy.
Rindt H; Feng Z; Mazzasette C; Glascock JJ; Valdivia D; Pyles N; Crawford TO; Swoboda KJ; Patitucci TN; Ebert AD; Sumner CJ; Ko CP; Lorson CL
Hum Mol Genet; 2015 Jul; 24(14):4094-102. PubMed ID: 25911676
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms and animal models of spinal muscular atrophy.
Edens BM; Ajroud-Driss S; Ma L; Ma YC
Biochim Biophys Acta; 2015 Apr; 1852(4):685-92. PubMed ID: 25088406
[TBL] [Abstract][Full Text] [Related]
14. Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.
Tseng YT; Chen CS; Jong YJ; Chang FR; Lo YC
Pharmacol Res; 2016 Sep; 111():58-75. PubMed ID: 27241020
[TBL] [Abstract][Full Text] [Related]
15. Spinal Muscular Atrophy: More than a Disease of Motor Neurons?
Nash LA; Burns JK; Chardon JW; Kothary R; Parks RJ
Curr Mol Med; 2016; 16(9):779-792. PubMed ID: 27894243
[TBL] [Abstract][Full Text] [Related]
16. SMN deficiency does not induce oxidative stress in SMA iPSC-derived astrocytes or motor neurons.
Patitucci TN; Ebert AD
Hum Mol Genet; 2016 Feb; 25(3):514-23. PubMed ID: 26643950
[TBL] [Abstract][Full Text] [Related]
17. Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy.
Sison SL; Patitucci TN; Seminary ER; Villalon E; Lorson CL; Ebert AD
Hum Mol Genet; 2017 Sep; 26(17):3409-3420. PubMed ID: 28637335
[TBL] [Abstract][Full Text] [Related]
18. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy.
Sapaly D; Dos Santos M; Delers P; Biondi O; Quérol G; Houdebine L; Khoobarry K; Girardet F; Burlet P; Armand AS; Chanoine C; Bureau JF; Charbonnier F; Lefebvre S
Sci Rep; 2018 Feb; 8(1):2075. PubMed ID: 29391529
[TBL] [Abstract][Full Text] [Related]
20. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
